On November 22, 2017 Bristol-Myers Squibb Company (NYSE:BMY) reported that it will take part in the Evercore ISI Biopharma Conference on Wednesday, November 29, 2017, in Boston. Fouad Namouni, senior vice president, head of Oncology Development, will answer questions about the company at 11:45 a.m. ET (Press release, Bristol-Myers Squibb, NOV 22, 2017, View Source [SID1234522221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

On November 22, 2017 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017, at 11:00 a.m. local time (8:00 a.m. Pacific time) in New York City (Press release, Ignyta, NOV 22, 2017, View Source [SID1234522224]) .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available during the presentation in the Investors section of the company’s website at View Source, and will be archived and available at that site for 14 days.

On November 22, 2017 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will present at the 2017 Piper Jaffray Healthcare Conference (Press release, Array BioPharma, NOV 22, 2017, View Source;p=RssLanding&cat=news&id=2318359 [SID1234522229]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:
Piper Jaffray Healthcare Conference
Presenter:
Ron Squarer, Chief Executive Officer
Date:
Wednesday, November 29, 2017
Time:
9:00 a.m. Eastern Time
Webcast:
View Source;tp_key=889917fd39

"Med introduktionen på First North tog Xspray Pharma ett viktigt steg mot att förverkliga målet att lansera våra tre första produkter på den amerikanska marknaden för cancerläkemedel 2020-2023 (Filing, Xspray, NOV 22, 2017, View Source [SID1234523281]). Verksamheten utvecklas enligt plan och vi arbetar nu med full kraft för att nå våra mål."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Per Andersson, VD, Xspray Pharma AB (publ)

Tredje kvartalet, jul-sep 2017

Tal inom parentes avser motsvarande period föregående år.

Resultat före skatt uppgick till –2 836 kSEK (–6 724).
Nettoomsättningen uppgick till 100 kSEK (-).
Resultat per aktie1) uppgick till –0,23 SEK (–1,69).
Kassaflöden från den löpande verksamheten uppgick till 46 kSEK (–5 077).
Xspray Pharmas aktier godkändes för notering på First North och började handlas den 28 september.
Inför börsintroduktionen genomfördes en nyemission som inbringade cirka 132 miljoner kronor före emissionskostnader. Bolaget hade efter transaktionen drygt 2 100 ägare.

De först nio månaderna, jan-sep 2017

Tal inom parentes avser motsvarande period föregående år.

Resultat före skatt uppgick till –8 487 kSEK (–13 873).
Nettoomsättningen uppgick till 311 kSEK (691).
Resultat per aktie1) uppgick till –0,69 SEK (–2,36).
Likvida medel uppgick vid periodens slut till 137 679 kSEK (9 371).
Totalt eget kapital uppgick till 161 151 kSEK (7 300).
Kassaflöden från den löpande verksamheten uppgick till –6 963 kSEK (–11 138).

Händelser efter den 30 september 2017

Den 24 oktober presenterade bolaget positiva kliniska resultat för HyNap-Dasa.
Bolaget erhöll godkännande för tre patent i USA avseende HyNap-Dasa, HyNap-Sora och HyNap-Nilo. Tidigare i oktober erhölls produktpatent för komposition och metod i Japan.

1) Resultat efter skatt delat med antalet aktier vid periodens slut.

Storägare utökar innehav i Xspray Pharma och ingår avtal om lock-up

För ytterligare information, vänligen kontakta:
Per Andersson, vd, Xspray Pharma AB (publ)
Mobil: +46 (0)706 88 23 48
E-mail: [email protected]

Denna information är sådan som Xspray Pharma AB ska offentliggöra enligt EU:s marknadsmissbruksförordning och lagen om värdepappersmarknaden. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 22 november 2017 kl. 08:00 CET

Xspray Pharma i korthet

Xspray Pharma AB (publ) är ett produktutvecklingsföretag med flera produktkandidater i klinisk utveckling. Xspray använder sin innovativa patenterade RightSize-teknologi för att utveckla förbättrade samt generiska versioner av marknadsförda cancerläkemedel, i första hand proteinkinashämmare (PKI), för behandling av cancer. Segmentet är det näst största inom onkologiområdet och läkemedelspriserna är mycket höga. Genom bolagets innovativa teknologi kan Xspray komma in som första konkurrent till dagens originalläkemedel utan hinder från sekundära patent. Xsprays mål är att ha tre produkter färdiga för lansering på den amerikanska marknaden under perioden 2020-2023, med en första produktlansering senast 2021. Bolaget har patent på tillverkningsteknologi, utrustning och de resulterande produkterna. Aktierna i Xspray Pharma AB (publ) handlas på Nasdaq First North Stockholm och Redeye är bolagets Certified Adviser.

On November 22, 2017 Nektar Therapeutics (Nasdaq: NKTR) reported several promotions on its executive leadership team (Press release, Nektar Therapeutics, NOV 22, 2017, View Source [SID1234522231]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stephen Doberstein, Ph.D., has been promoted to Senior Vice President, Research & Development and Chief Research & Development Officer;
Mary Tagliaferri, M.D., has been promoted to Senior Vice President, Clinical Development and Chief Medical Officer;
Jonathan Zalevsky, Ph.D., has been promoted to Senior Vice President, Research and Chief Scientific Officer.
"I am exceptionally pleased to announce today’s promotions which highlight the talent, skill set and extensive achievements of our executive team," said Howard W. Robin, President and CEO of Nektar Therapeutics. "With the growth in the development of Nektar’s unique and wholly-owned immuno-oncology portfolio and our submission of an NDA filing for NKTR-181, it is critical that we have the right leadership in place to drive the continued success of our pipeline and the company."

Dr. Doberstein has over 25 years of experience in biotechnology research and development. Since joining Nektar in January 2010, he has spearheaded the discovery team at Nektar, which led to the identification and growth of the company’s proprietary pipeline of drug candidates. This included development of NKTR-181 (a first-in-class opioid analgesic with strategic brain entry kinetics) and NKTR-214 (a CD122-biased agonist that is currently in multiple clinical studies across a wide range of tumor types). Dr. Doberstein also serves as a representative of Nektar for the National Institute of Health (NIH) Public/Private Initiative to Address the Opioid Crisis. Prior to joining Nektar, Dr. Doberstein was Vice President of Research at XOMA where he was responsible for directing discovery and development of multiple drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and pharmacokinetics/pharmacodynamics. Previously, Dr. Doberstein served as Vice President, Research at Five Prime Therapeutics, a protein and antibody discovery and development company where he built and led the discovery research and process development group. While at Five Prime, he created several successful drug candidate programs that resulted in multiple strategic alliances with pharmaceutical partners, and moved a number of product candidates from concept to clinical stage in diabetes, oncology, rheumatoid arthritis and osteoarthritis. Prior to that, Dr. Doberstein was the Vice President of Research at Xencor, and also held senior leadership positions at Exelixis.

Dr. Tagliaferri has 20 years of experience in pharmaceutical drug development in oncology and women’s health as well as extensive regulatory expertise. Dr. Tagliaferri joined Nektar in January 2015 as Vice President, Clinical Development. During her tenure at Nektar, she has provided strategic development leadership for the company’s immuno-oncology portfolio, including NKTR-214, a CD122 biased agonist, which is in multiple clinical studies across a wide range of tumor types. She serves as strategic development leader for the clinical collaboration between Nektar and Bristol-Myers Squibb. Prior to joining Nektar, she was a clinical and regulatory consultant to InterMune before its acquisition by Roche. She also served as Chief Medical Officer at KangLaiTe USA, a privately-held biotechnology company which develops oncology drug candidates in multiple solid tumor settings. Dr. Tagliaferri was also co-founder and President and Chief Medical Officer of BioNovo where she led the company’s clinical drug development strategy and global regulatory affairs, led data management and biostatistics, and oversaw clinical operations and compliance. Dr. Tagliaferri received the 2012 State of California Woman of the Year award for her advancements of clinical research in women’s health and her mentorship of women in the biotechnology field.

Dr. Zalevsky joined Nektar in July 2015 as Vice President of Biology and Preclinical Development to lead biological and translational research and guide strategy for the Nektar discovery portfolio. During his tenure at the company, Dr. Zalevsky’s expertise in immunology, as well as his experience across biological modalities and therapeutic areas, have helped fuel the growth of the company’s immuno-oncology and immunology pipeline. Dr. Zalevsky led the discovery and preclinical development for NKTR-358 (a T regulatory cell stimulatory agent being developed for auto-immune diseases with partner Eli Lilly & Co.) and NKTR-262 (a small molecule TLR agonist being developed in combination with NKTR-214). Prior to joining Nektar, Dr. Zalevsky had over 15 years of experience within both large pharmaceutical and small biotechnology companies. Previously, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development and launched products. Prior to working at Takeda, Dr. Zalevsky held a number of research and development positions at Xencor, where he was responsible for the discovery and development of Xencor’s first four clinical-stage assets.